4/A: OPKO Health CEO Phillip Frost Increases Stake in Company

OPKO Health's CEO and Chairman, Phillip Frost, has increased his holdings in the company through a series of transactions, including a direct purchase of 280,183 shares.

Summary

• Phillip Frost, CEO and Chairman of OPKO Health, has reported changes in his beneficial ownership of the company's stock.
• On November 8, 2024, Mr. Frost directly purchased 280,183 shares of common stock at a weighted average price of $1.5045 per share.
• These shares were purchased in multiple transactions with prices ranging from $1.455 to $1.545.
• Following the transaction, Mr. Frost's indirect holdings include 211,512,405 shares held by Frost Gamma Investments Trust and 30,127,177 shares held by Frost Nevada Investments Trust.
• Mr. Frost also directly owns 3,568,951 shares.
• This filing is an amendment to a previous filing on November 8, 2024, to correct the number of directly owned shares due to a scrivener's error.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive sign, but the filing is primarily a routine disclosure of insider trading activity.

Positives

• The CEO's purchase of shares indicates confidence in the company's future prospects.
• The increased stake by the CEO could be seen as a positive signal to the market.

Risks

• The document does not explicitly state any risks, but the reliance on a single individual's transactions could be a risk factor.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4, upon request.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in the pharmaceutical and healthcare industry. It is important for investors to monitor these filings to understand the sentiment of key company personnel.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for publicly traded companies, and this filing is consistent with SEC regulations.
• Similar filings are made by executives at comparable companies such as Teva Pharmaceuticals and Mylan, when they buy or sell shares in their respective companies.

Stakeholder Impact

• The increased stake by the CEO could positively influence shareholder confidence.
• The disclosure provides transparency to all stakeholders regarding insider transactions.

Key Dates

Keywords

OPKO Health, Phillip Frost, insider trading, share purchase, beneficial ownership, stock transaction, SEC Form 4